

# Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/R97AF824A18EN.html>

Date: May 2021

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: R97AF824A18EN

## Abstracts

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company's lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca, Kissei, Grifols, Merck and Novartis. Rigel is headquartered in South San Francisco, California, the US.

### Rigel Pharmaceuticals Inc Key Recent Developments

Apr 28,2021: Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Mar 02,2021: Rigel reports fourth quarter and full year 2020 financial results and provides business update

Feb 23,2021: Rigel Announces Conference Call and Webcast to Report Fourth Quarter

and Year End 2020 Financial Results and Business Update

Feb 19,2021: Lilly, Rigel enter \$960m deal to develop RIPK1 inhibitors

May 05,2020: Rigel reports first quarter 2020 financial results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Rigel Pharmaceuticals Inc - Key Facts  
Rigel Pharmaceuticals Inc - Key Employees  
Rigel Pharmaceuticals Inc - Key Employee Biographies  
Rigel Pharmaceuticals Inc - Major Products and Services  
Rigel Pharmaceuticals Inc - History  
Rigel Pharmaceuticals Inc - Company Statement  
Rigel Pharmaceuticals Inc - Locations And Subsidiaries  
Head Office

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Rigel Pharmaceuticals Inc - Business Description  
Business Segment: Contract revenues from collaborations  
Performance  
Business Segment: Product sales  
Performance  
Rigel Pharmaceuticals Inc - Corporate Strategy  
Rigel Pharmaceuticals Inc - SWOT Analysis  
SWOT Analysis - Overview  
Rigel Pharmaceuticals Inc - Strengths  
Rigel Pharmaceuticals Inc - Weaknesses  
Rigel Pharmaceuticals Inc - Opportunities  
Rigel Pharmaceuticals Inc - Threats  
Rigel Pharmaceuticals Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Rigel Pharmaceuticals Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Apr 28, 2021: Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Mar 02, 2021: Rigel reports fourth quarter and full year 2020 financial results and provides business update

Feb 23, 2021: Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update

Feb 19, 2021: Lilly, Rigel enter \$960m deal to develop RIPK1 inhibitors

May 05, 2020: Rigel reports first quarter 2020 financial results and provides business update

Feb 27, 2020: Rigel reports fourth quarter and full year 2019 financial results and provides business update

Jan 13, 2020: Rigel Pharmaceuticals provides business update

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Rigel Pharmaceuticals Inc, Key Facts  
Rigel Pharmaceuticals Inc, Key Employees  
Rigel Pharmaceuticals Inc, Key Employee Biographies  
Rigel Pharmaceuticals Inc, Major Products and Services  
Rigel Pharmaceuticals Inc, History  
Rigel Pharmaceuticals Inc, Key Competitors  
Rigel Pharmaceuticals Inc, Ratios based on current share price  
Rigel Pharmaceuticals Inc, Annual Ratios  
Rigel Pharmaceuticals Inc, Annual Ratios (Cont...1)  
Rigel Pharmaceuticals Inc, Interim Ratios  
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Rigel Pharmaceuticals Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Rigel Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Rigel Pharmaceuticals Inc, Ratio Charts

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/R97AF824A18EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R97AF824A18EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970